Get to know us
We started as a small neuroscience-driven research initiative, rooted in the belief that the brain can regenerate — it just needs the right molecular tools.
Initially focused on theoretical modeling and in silico drug design, we quickly recognized that no existing therapies truly addressed the root cause of neurological decline: the loss of neuroplasticity. From there, NeuroVista Labs was born.
Today, we are a Brazilian biotech developing next-generation, brain-penetrant TrkB agonists — small molecules designed to restore neural adaptability in conditions like Alzheimer’s disease and treatment-resistant depression. Our goal is to move beyond symptom relief and build real regenerative solutions for the human brain.
Our mission
To develop next-generation therapeutics that restore neuroplasticity in complex neurological disorders through selective TrkB activation.
We are committed to designing safe, effective, and scalable small molecules that address the root causes of neurodegeneration and emotional dysregulation.
Our vision
To redefine the treatment of brain disorders by unlocking the regenerative potential of the nervous system.
We aim to become a global leader in neuroplasticity-based therapeutics, transforming how conditions like Alzheimer’s disease and treatment-resistant depression are understood and treated.
Our Founder
Ravi Kaiut, is a neuroscientist and health innovator with over 10 years of experience in neuroplasticity and regenerative health, NeuroVista emerged from a deep commitment to solving what traditional approaches have failed to address: the progressive collapse of neural adaptability in conditions like Alzheimer’s and treatment-resistant depression.
Under Ravi’s leadership, our team combines computational modeling, medicinal chemistry, and translational neuroscience to design highly selective, brain-penetrant TrkB agonists — small molecules capable of restoring plasticity where it breaks down most.
What began as an independent research initiative is now a biotech platform with global potential. Today, NeuroVista is advancing a new generation of orally available TrkB activators, built for real-world use, real-life patients, and real impact.
Ravi K. T Kaiut
Founder and lead researcher
Contact
Get in touch for partnership and inquiries.
info@neurovistalabs.com.br
+1 (786) 979-7926
© 2025. All rights reserved.